List view / Grid view
Pfizer Inc. announced it has completed the submission of a…
19 August 2014 | By Pfizer
Pfizer Inc. announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration for palbociclib...
“BOSULIF is the third new medicine to be approved by…
4 September 2012 | By Pfizer
“BOSULIF is the third new medicine to be approved by the FDA in just 13 months..."
The U.S. FDA has accepted its NDA for standard review…
27 January 2012 | By Pfizer
The U.S. FDA has accepted its NDA for standard review of bosutinib...
First treatment to demonstrate superior benefit in a Phase 3…
27 January 2012 | By Pfizer
First treatment to demonstrate superior benefit in a Phase 3 study compared with another targeted agent in advanced RCC...
SFJ announced that it has entered into a collaborative development…
9 January 2012 | By Citigate Dewe Rogerson
SFJ announced that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial...
The U.S. FDA has accepted Pfizer’s filing for standard review…
28 June 2011 | By Pfizer
The U.S. FDA has accepted Pfizer’s filing for standard review of axitinib for patients with advanced RCC...
